Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!

Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials

Published on Jul 1, 2018in International Clinical Psychopharmacology 1.64
· DOI :10.1097/yic.0000000000000217
Susan G. Kornstein40
Estimated H-index: 40
,
Cheng-Tao Chang1
Estimated H-index: 1
+ 1 AuthorsJohn Edwards3
Estimated H-index: 3
Cite
  • References (0)
  • Citations (1)
Cite
References0
Newest
Cited By1
Newest
Published on Feb 11, 2019in Expert Opinion on Pharmacotherapy 3.04
Mirella Stuivenga1
Estimated H-index: 1
(University of Antwerp),
Erik J. Giltay51
Estimated H-index: 51
(LUMC: Leiden University Medical Center)
+ 3 AuthorsBernard Sabbe38
Estimated H-index: 38
(University of Antwerp)
ABSTRACTIntroduction: Major Depressive Disorder (MDD) and General Anxiety Disorder (GAD) significantly contribute to the global burden of disease. Vilazodone, a combined serotonin reuptake inhibitor and 5-HT1A partial agonist, is an approved therapy for the treatment of MDD and which has been further investigated for GAD.Areas covered: This article covers the pharmacokinetics and pharmacodynamics of vilazodone and provides an evaluation of the clinical usefulness of vilazodone for the treatment ...